D. Zheleva

发表

The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A.

T. Hupp, M. Luciani, J. R. Hutchins, 2000, Journal of molecular biology.

Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents.

Peter M Fischer, Wayne Jackson, Campbell McInnes, 2010, Chemistry & biology.

In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine)

Nikolai Zhelev, Shudong Wang, D. Zheleva, 2002, International journal of cancer.

Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop.

Su-Ying Wu, P. Taylor, D. Lane, 2003, Structure.

2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity.

A. Osnowski, Su-Ying Wu, M. Walkinshaw, 2004, Journal of medicinal chemistry.

Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design.

Su-Ying Wu, P. Taylor, D. Lane, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Targeting glycogen synthase kinase-3 in insulin signalling

D. Zheleva, S. Frame, 2006, Expert opinion on therapeutic targets.

Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding.

Paul N Barlow, Campbell McInnes, Helen Powers, 2005, Journal of molecular biology.

Liquid‐phase peptide synthesis on polyethylene glycol (PEG) supports using strategies based on the 9‐fluorenylmethoxycarbonyl amino protecting group: application of PEGylated peptides in biochemical assays

D. Zheleva, P. Fischer, P. Fischer, 2002, Journal of peptide science : an official publication of the European Peptide Society.

The structure, function and dynamics of photosystem two

J. Barber, D. Zheleva, J. Nield, 1997 .

Mitotic entry: Non-genetic heterogeneity exposes the requirement for Plk1

Stephen S. Taylor, D. Zheleva, A. Tighe, 2015, Oncotarget.

Investigating the protective role of phosphorylation for PSII complexes

J. Barber, D. Zheleva, O. Kruse, 1995 .

Use of peptides from p21 (Waf1/Cip1) to investigate PCNA function in Xenopus egg extracts.

P. Jares, D. Lane, D. Zheleva, 2001, Experimental cell research.

Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit.

D. Lane, D. Zheleva, P. Fischer, 2003, Current medicinal chemistry. Anti-cancer agents.

Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells

D. Zheleva, W. Plunkett, D. Blake, 2022, Leukemia.

Biochemical characterisation of LHCII-PSII complexes associated with and lacking the 33kD subunit

J. Barber, D. Zheleva, E. Boekema, 1995 .

Biochemical characterisation and structural analysis of monomeric and dimeric photosystem II core preparations

J. Barber, D. Zheleva, B. Hankamer, 1995 .

Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors.

Peter M Fischer, Wayne Jackson, Campbell McInnes, 2010, Journal of medicinal chemistry.

Peptide inhibitors of CDK2-cyclin A that target the cyclin recruitment-site: structural variants of the C-terminal Phe.

D. Zheleva, P. Fischer, C. McInnes, 2002, Bioorganic & medicinal chemistry letters.

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma

Charles Y. Lin, J. Bradner, N. Gray, 2020, The Journal of clinical investigation.

Isolation and biochemical characterisation of monomeric and dimeric photosystem II complexes from spinach and their relevance to the organisation of photosystem II in vivo.

J. Barber, D. Zheleva, E. Boekema, 1997, European journal of biochemistry.

An integrated pharmacokinetic–pharmacodynamic model for an Aurora kinase inhibitor

R. Jackson, D. Zheleva, F. A. Davidson, 2010, Journal of Pharmacokinetics and Pharmacodynamics.

A quantitative study of the in vitro binding of the C-terminal domain of p21 to PCNA: affinity, stoichiometry, and thermodynamics.

D. Lane, D. Zheleva, P. Fischer, 2000, Biochemistry.

Aurora kinase inhibitors: Progress towards the clinic

D. Zheleva, P. Džubák, M. Lepšík, 2012, Investigational New Drugs.

Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML

M. Copland, D. Zheleva, Y. Hsieh, 2021, Cell death discovery.

Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors.

D. Lane, R. Jackson, D. Zheleva, 2010, Journal of medicinal chemistry.

Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer

P. Workman, D. Zheleva, D. Blake, 2020, PloS one.

Abstract 1650: CYC065, a novel CDK2/5/9 inhibitor: detailed mechanistic studies, determinants of sensitivity and synergistic combinations

D. Zheleva, D. Blake, S. Frame, 2015 .

CYC065, potential therapeutic agent for AML and MLL leukaemia

D. Zheleva, D. Blake, S. Frame, 2015 .

Aurora kinases: structure, functions and their association with cancer.

D. Zheleva, P. Džubák, M. Kollareddy, 2008, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma

K. Ligon, D. Zheleva, M. Rehm, 2019, Cancers.

Identification and characterization of drug resistance mechanisms in cancer cells against Aurora kinase inhibitors CYC116 and ZM447439

D. Zheleva, L. Radová, J. Srovnal, 2020, bioRxiv.

The p53-Mdm2 pathway: targets for the development of new anticancer therapeutics.

D. Lane, D. Zheleva, P. Fischer, 2003, Mini reviews in medicinal chemistry.

Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells

D. Zheleva, D. Jodrell, B. Krippendorff, 2012, British Journal of Cancer.

In vivo mode of action of CYC116, a novel small molecule inhibitor of Aurora kinases and VEGFR2

D. Zheleva, I. Stuart, P. Džubák, 2008 .

Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange.

D. Lane, M. Walkinshaw, D. Zheleva, 2003, Structure.

Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A.

D. Lane, D. Zheleva, P. Fischer, 2002, The journal of peptide research : official journal of the American Peptide Society.

Abstract #3863: Derivatives of seliciclib with improved potency both in vitro and in vivo as novel cyclin dependent kinase (CDK) inhibitors

P. Workman, D. Zheleva, D. Maccallum, 2009 .

Abstract CT050: Expansion cohort of Phase I study of oral sapacitabine and oral seliciclib in patients with metastatic breast cancer andBRCA1/2mutations

David R. Liu, E. Winer, G. Shapiro, 2019, Clinical Trials.

Abstract CT037: Phase I safety, pharmacokinetic and pharmacodynamic study of CYC065, a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953)

G. Shapiro, D. Zheleva, D. Blake, 2018, Clinical Trials.

Phase 1 safety, pharmacokinetic and pharmacodynamic study of fadraciclib (CYC065), a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953)

G. Shapiro, D. Zheleva, D. Blake, 2020 .

Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents.

D. Lane, R. Jackson, D. Zheleva, 2010, Chemistry & biology.

Combination of CYC065, a Second Generation CDK2/9 Inhibitor, with Venetoclax or Standard Chemotherapies - a Novel Therapeutic Approach for Acute Myeloid Leukaemia (AML)

M. Copland, D. Zheleva, Y. Hsieh, 2019, Blood.